Home

Reels

Events

Discover Events My Events

Blogs

Discover Blogs

Market

Discover Market

Groups

Discover Groups My Groups

Pages

Discover Pages Liked Pages

More

Popular Posts Discover Posts Funding Offers Jobs Courses Forums Movies Games Merits
Market Blogs Pages Groups
Events Jobs Offers See All

Upgrade to Pro
Sofia Smith added blog Home
2022-12-21 11:18:47
In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.
In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.
Progressive Supranuclear Palsy (PSP) Therapies market Size, Share and Industry Trends by 2030
Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031Since John Steele, John Richardson, and Jerzy Olszewski first described PSP in 1964, the neuroscience community has been on the lookout to find a “miracle molecule” or an “elixir” that can cure patients diagnosed with this debilitating disease.With more than 2,000 research studies published...
·3K Views ·0 Reviews
Please log in to like, share and comment!